Brain and Gut Plasticity in Mild TBI Following Growth Hormone Therapy
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Patients with a history of mild traumatic brain injury (mTBI) and abnormal growth hormone
secretion, as measured by glucagon stimulation test, will be treated with replacement growth
hormone therapy for a period of 6 months. Testing of cognition, exercise, fatigue, brain
activation and morphology, body composition and measurements of quality of life will be
performed before and after the treatment period. Fecal sampling for characterization of the
GI microbiome will occur monthly over the treatment period. Each mTBI subject will be
required to enroll with an eligible control from their household that will also provide fecal
samples monthly during the treatment period of their mTBI partner. GI microbiomes will be
compared between mTBI patients and their household controls at baseline as well as over the
treatment period.